IDEXX Laboratories, Inc. (IDXX) Q3 FY2026 earnings

Reported results

• Third quarter 2026 revenues were $1,214 million, an increase of 10% as reported and 10% for organic revenue growth (non-GAAP).
• Earnings per diluted share (EPS) were $4.01 as reported (GAAP), up 18%, while comparable EPS (non-GAAP) was $3.96, up 22% on a comparable basis.
• Gross margin was 62.9% as reported (GAAP), an increase of 110 basis points, and comparable gross margin (non-GAAP) was 62.7%, up 90 basis points on a comparable basis.
• Operating margin was 33.1% as reported (GAAP), up 100 basis points, while comparable operating margin (non-GAAP) was 32.7%, up 60 basis points on a comparable basis.
• CAG Diagnostics recurring revenue was $967,351 thousand for the quarter, an increase of 11% as reported and organic (non-GAAP).

Guidance

• Updated 2026 revenue guidance range to $4,741 million - $4,767 million, representing reported revenue growth of 10.1% - 10.8% and projected organic revenue growth (non-GAAP) of 9.3% - 10.0%.
• Updated 2026 CAG Diagnostics recurring revenue reported growth outlook to 11.0% - 11.7%, with projected organic growth (non-GAAP) of 10.3% - 11.0%.
• Updated 2026 reported operating margin outlook to 32.1% - 32.3%, with projected operating margin expansion of 50 bps - 70 bps as reported and on a comparable basis (non-GAAP).
• Updated 2026 EPS outlook range to $14.96 - $15.16, reflecting reported EPS growth of 14% - 16% and comparable EPS growth (non-GAAP) of 15% - 16%.

Price and volatility reaction

The stock moved +21.9% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved +2.2 vol points across the event (constant-maturity series — not the front-week crush).

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-02 (8-K, Item 2.02). Read the original filing on sec.gov.